

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address COMMISSIONER FOR PATENTS PO Box 1450 Alexandra, Virginia 22313-1450 www.wepto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/583,093	06/15/2006	Andreas Nandy	MERCK-3179	1555	
23599 MILLEN, WHITE, ZELANO & BRANIGAN, P.C. 2200 CLARENDON BLVD. SUITE 1400 ARLINGTON, VA 22201			EXAM	EXAMINER	
			ROONEY, NORA MAUREEN		
			ART UNIT	PAPER NUMBER	
			1644		
			MAIL DATE	DELIVERY MODE	
			03/31/2008	PAPER	

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Application No. Applicant(s) 10/583.093 NANDY ET AL. Office Action Summary Examiner Art Unit NORA M. ROONEY 1644 -- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --Period for Reply A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS. WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION. Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b). Status 1) Responsive to communication(s) filed on 30 January 2007. 2a) This action is FINAL. 2b) This action is non-final. 3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213. Disposition of Claims 4) Claim(s) 1-17 is/are pending in the application. 4a) Of the above claim(s) is/are withdrawn from consideration. 5) Claim(s) _____ is/are allowed. 6) Claim(s) _____ is/are rejected 7) Claim(s) is/are objected to. 8) Claim(s) 1-17 are subject to restriction and/or election requirement. Application Papers 9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are; a) accepted or b) objected to by the Examiner. Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d). 11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152. Priority under 35 U.S.C. § 119 12) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a) All b) Some * c) None of: Certified copies of the priority documents have been received. 2. Certified copies of the priority documents have been received in Application No. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received.

Application/Control Number: 10/583,093 Page 2

Art Unit: 1644

DETAILED ACTION

Applicant is reminded that "use" claims are non-statutory and are not appropriate for US practice (see MPEP 2173.05(q)). For examination purposes "use" claims are interpreted as a method of the first recited "use"

Election/Restrictions

- Restriction to one of the following inventions is required under 35 U.S.C. § 121:
 - I. Claims 1-9 and 14-16, drawn to a DNA molecule encoding Lol p 4 or a fragment thereof; complements, vectors, host cells, methods of producing the polypeptide, and composition and medicaments comprising the DNA or vector, classified in Class 536, subclass 23.1; Class 435, subclasses 69.1 and 252.3; Class 514, subclass 44.
 - II. Claims 10-12, drawn to the Lol p 4 polypeptide encoded by SEQ ID NO:1 or SEQ ID NO:3 and composition and medicaments thereof; classified in Class 530, subclass 350, Class 424, subclasses 185.1 and 275.1; and Class 514, subclass 2.
 - III. Claim 13, drawn to a method of using the polypeptide encoded by SEQ ID NO:1 or SEQ ID NO:3 for the diagnosis and/or treatment of allergies, classified in Class 435, subclass 7.1; Class 530, subclass 350, Class 424, subclasses 185.1 and 275.1; and Class 514, subclass 2.

Page 3

Application/Control Number: 10/583,093

Art Unit: 1644

IV. Claim 17, drawn to a method of using the DNA of SEQ ID NO:1 or SEQ ID NO:3 for immunotherapeutic DNA vaccination, classified in Class 536, subclass 23.1; and Class 514, subclass 44.

- 3. Restriction for examination purposes as indicated is proper because all these inventions listed in this action are independent or distinct for the reasons given above and there would be a serious search and examination burden if restriction were not required because one or more of the following reasons apply:
 - (a) the inventions have acquired a separate status in the art in view of their different classification;
 - (b) the inventions have acquired a separate status in the art due to their recognized divergent subject matter;
 - (c) the inventions require a different field of search (for example, searching different classes/subclasses or electronic resources, or employing different search queries);
 - (d) the prior art applicable to one invention would not likely be applicable to another invention;
 - (e) the inventions are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete <u>must</u> include

(i) an election of a invention to be examined even though the requirement may be traversed (37

CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

Application/Control Number: 10/583,093

Art Unit: 1644

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected invention.

If claims are added after the election, applicant must indicate which of these claims are readable upon the elected invention.

Should applicant traverse on the ground that the inventions are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

This application contains claims directed to the following patentably distinct species:

If Applicant elects either of Groups I or IV, Applicant is further required to elect: a single specific DNA molecule (SEQ ID NO:1 or SEQ ID NO:3). Application/Control Number: 10/583,093

Art Unit: 1644

If Applicant elects any of Groups II or III, Applicant is further required to elect:

a single specific polypeptide (encoded by SEQ ID NO:1 or SEQ ID NO:3).

The species are independent or distinct because claims to the different species recite the

mutually exclusive characteristics of such species. In addition, these species are not obvious

variants of each other based on the current record.

Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution

on the merits to which the claims shall be restricted if no generic claim is finally held to be

allowable.

There is an examination and search burden for these patentably distinct species due to their

mutually exclusive characteristics. The species require a different field of search (e.g., searching

different classes/subclasses or electronic resources, or employing different search queries);

and/or the prior art applicable to one species would not likely be applicable to another species;

and/or the species are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35

U.S.C. 112, first paragraph.

Applicant is advised that the reply to this requirement to be complete must include

(i) an election of a species to be examined even though the requirement may be traversed (37

CFR 1.143) and (ii) identification of the claims encompassing the elected species, including

Application/Control Number: 10/583,093

Art Unit: 1644

any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

The election of the species may be made with or without traverse. To preserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the election of species requirement, the election shall be treated as an election without traverse. Traversal must be presented at the time of election in order to be considered timely. Failure to timely traverse the requirement will result in the loss of right to petition under 37 CFR 1.144. If claims are added after the election, applicant must indicate which of these claims are readable on the elected species.

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the species unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other species.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which depend from or otherwise require all the limitations of an allowable generic claim as provided by 37 CFR 1.141.

Page 7

Application/Control Number: 10/583,093

Art Unit: 1644

5. The examiner has required restriction between product and process claims. Where applicant elects claims directed to the product, and the product claims are subsequently found allowable, withdrawn process claims that depend from or otherwise require all the limitations of the allowable product claim will be considered for rejoinder. All claims directed a nonelected process invention must require all the limitations of an allowable product claim for that process invention to be rejoined.

In the event of rejoinder, the requirement for restriction between the product claims and the rejoined process claims will be withdrawn, and the rejoined process claims will be fully examined for patentability in accordance with 37 CFR 1.104. Thus, to be allowable, the rejoined claims must meet all criteria for patentability including the requirements of 35 U.S.C. 101, 102, 103 and 112. Until all claims to the elected product are found allowable, an otherwise proper restriction requirement between product claims and process claims may be maintained.

Withdrawn process claims that are not commensurate in scope with an allowable product claim will not be rejoined. See MPEP § 821.04(b). Additionally, in order to retain the right to rejoinder in accordance with the above policy, applicant is advised that the process claims should be amended during prosecution to require the limitations of the product claims. Failure to do so may result in a loss of the right to rejoinder. Further, note that the prohibition against double patenting rejections of 35 U.S.C. 121 does not apply where the restriction requirement is withdrawn by the examiner before the patent issues. See MPEP § 804.01.

Page 8

Application/Control Number: 10/583,093

Art Unit: 1644

 Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the

currently named inventors is no longer an inventor of at least one claim remaining in the

application. Any amendment of inventorship must be accompanied by a request under 37 CFR

1.48(b) and by the fee required under 37 CFR 1.17(i).

7. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to Nora M. Rooney whose telephone number is (571) 272-9937.

The examiner can normally be reached Monday through Friday from 8:30 am to 5:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by

telephone are unsuccessful, the examiner's supervisor, Eileen O'Hara can be reached on (571)

272-0878. The fax number for the organization where this application or proceeding is assigned

is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent

Application Information Retrieval (PAIR) system. Status information for published applications

 $may\ be\ obtained\ from\ either\ Private\ PAIR\ or\ Public\ PAIR.\ \ Status\ information\ for\ unpublished$

applications is available through Private PAIR only. For more information about the PAIR

system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

March 25, 2008 Nora M. Rooney, M.S., J.D.

Patent Examiner

Technology Center 1600

/Maher M. Haddad/ Primary Examiner, Art Unit 1644